This “Sigma-1 receptor agonists - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Sigma-1 receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Sigma-1 receptor agonists Understanding
Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD). Sigma-1 receptor is a 223 amino acid-long transmembrane protein residing in the ER membrane. S1R preferentially localizes to the specific microdomains of the ER called mitochondrial-associated membranes (MAM), where it can regulate InsP3R-dependent calcium flux from the ER to mitochondria, lipid dynamics, MAM stability, and the ER stress response. S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic.
Report Highlights
This segment of the Sigma-1 receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sigma-1 receptor agonists Emerging Drugs
Fenfluramine: Zogenix
Fenfluramine is a phenethylamine that is structurally similar to serotonin. Due to its ability to increase extracellular serotonin levels, modulate serotonergic and other neurologic receptors, and control neurotransmission, it is effective in treating pharmacoresistant seizures. Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of Dravet syndrome patients through the restricted FINTEPLA REMS program. It is currently sold under the name FINTEPLA® by Zogenix INC. Currently, it is in preregistration stage of development to treat Lennox-Gastaut syndrome.
Pridopidine: Prilenia Therapeutics
Pridopidine is currently being assessed in the ongoing phase 3 global clinical trial PROOF-HD (PRidopidine Outcome On Function in Huntington's Disease). The successful outcome of PROOF-HD may lead to its approval as a treatment for Huntington's Disease. The purpose of the study is to evaluate the effect of pridopidine on functional capacity, as well as on motor and behavioral features over 65 weeks. In prior clinical trials in HD patients, pridopidine demonstrated a beneficial effect in maintaining functional capacity after 1 year.
This segment of the report provides insights about the different Sigma-1 receptor agonists drugs segregated based on following parameters that define the scope of the report.
There are approx. 6+ key companies which are developing the Sigma-1 receptor agonists. The companies which have their Sigma-1 receptor agonists drug candidates in the most advanced stage, i.e. Preregistration include, Zogenix.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sigma-1 receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sigma-1 receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sigma-1 receptor agonists drugs.
Geography Covered
- Global coverage
Sigma-1 receptor agonists Understanding
Sigma-1 receptor agonists: Overview
Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD). Sigma-1 receptor is a 223 amino acid-long transmembrane protein residing in the ER membrane. S1R preferentially localizes to the specific microdomains of the ER called mitochondrial-associated membranes (MAM), where it can regulate InsP3R-dependent calcium flux from the ER to mitochondria, lipid dynamics, MAM stability, and the ER stress response. S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sigma-1 receptor agonists R&D. The therapies under development are focused on novel approaches for Sigma-1 receptor agonists.
Sigma-1 receptor agonists Emerging Drugs Chapters
This segment of the Sigma-1 receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sigma-1 receptor agonists Emerging Drugs
Fenfluramine: Zogenix
Fenfluramine is a phenethylamine that is structurally similar to serotonin. Due to its ability to increase extracellular serotonin levels, modulate serotonergic and other neurologic receptors, and control neurotransmission, it is effective in treating pharmacoresistant seizures. Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of Dravet syndrome patients through the restricted FINTEPLA REMS program. It is currently sold under the name FINTEPLA® by Zogenix INC. Currently, it is in preregistration stage of development to treat Lennox-Gastaut syndrome.
Pridopidine: Prilenia Therapeutics
Pridopidine is currently being assessed in the ongoing phase 3 global clinical trial PROOF-HD (PRidopidine Outcome On Function in Huntington's Disease). The successful outcome of PROOF-HD may lead to its approval as a treatment for Huntington's Disease. The purpose of the study is to evaluate the effect of pridopidine on functional capacity, as well as on motor and behavioral features over 65 weeks. In prior clinical trials in HD patients, pridopidine demonstrated a beneficial effect in maintaining functional capacity after 1 year.
Sigma-1 receptor agonists: Therapeutic Assessment
This segment of the report provides insights about the different Sigma-1 receptor agonists drugs segregated based on following parameters that define the scope of the report.
Major Players working on Sigma-1 receptor agonists
There are approx. 6+ key companies which are developing the Sigma-1 receptor agonists. The companies which have their Sigma-1 receptor agonists drug candidates in the most advanced stage, i.e. Preregistration include, Zogenix.
Phases
This report covers around 6+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Sigma-1 receptor agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sigma-1 receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sigma-1 receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sigma-1 receptor agonists drugs.
Sigma-1 receptor agonists Report Insights
- Sigma-1 receptor agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Sigma-1 receptor agonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing Sigma-1 receptor agonists drugs?
- How many Sigma-1 receptor agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sigma-1 receptor agonists?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sigma-1 receptor agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sigma-1 receptor agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Zogenix
- Prilenia Therapeutics
- Algernon Pharmaceuticals
- Anavex Life Sciences
- Axsome Therapeutics
- Proximagen
- Avanir Pharmaceuticals
Key Products
- Fenfluramine
- Pridopidine
- NP 120
- ANA001-HCl
- AXS-05
- ANAVEX 3-71
- PRX-00023
- AVP-786
- ANAVEX 2-73/DPZ
Table of Contents
IntroductionExecutive Summary
Sigma-1 receptor agonists: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Sigma-1 receptor agonists - Analytical Perspective
Late Stage Products (Preregistration)
- Comparative Analysis
Fenfluramine: Zogenix
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Ifenprodil: Algernon Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
ANAVEX 3-71: Anavex Life Sciences
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Sigma-1 receptor agonists Key Companies
Sigma-1 receptor agonists Key Products
Sigma-1 receptor agonists- Unmet Needs
Sigma-1 receptor agonists- Market Drivers and Barriers
Sigma-1 receptor agonists- Future Perspectives and Conclusion
Sigma-1 receptor agonists Analyst Views
Sigma-1 receptor agonists Key Companies
AppendixList of Tables
Table 1 Total Products for Sigma-1 receptor agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Sigma-1 receptor agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Zogenix
- Prilenia Therapeutics
- Algernon Pharmaceuticals
- Anavex Life Sciences
- Axsome Therapeutics
- Proximagen
- Avanir Pharmaceuticals
